SearcharxivSearch

arXiv subjects

Emily Hsiao

Publications and source records attributed to Emily Hsiao.

2 recordsLinked to original sources

A Functional-Class Meta-Analytic Framework for Quantifying Surrogate Resilience

A surrogate marker is a biomarker or other physical measurement used to replace a primary outcome in clinical trials to evaluate a treatment effect when the primary outcome of interest is costly, invasive, or takes a long time to observe. However, replacing a primary outcome with a surrogate can lead to the "surrogate paradox," in which a treatment appears beneficial based on the surrogate but is actually harmful with respect to the primary outcome. In this paper, we propose a functional class-based method to assess resilience to the surrogate paradox in a meta-analytic setting. Our method leverages data from K completed studies in which the surrogate marker and primary outcome have been measured to make inference on a new study in which only the surrogate is measured. We do not assume direct transportability of the conditional mean function from the completed studies to the new study; instead, we consider deviations of functions from those observed in the completed studies to estimate the "resilience probability" i.e., the probability of the surrogate paradox in the new study. We investigate the performance of our proposed method through a simulation study and apply our method to data from clinical trials in schizophrenia.

stat.ME

Resilience Measures for the Surrogate Paradox

Surrogate markers are often used in clinical trials to evaluate treatment effects when primary outcomes are costly, invasive, or take a long time to observe. However, reliance on surrogates can lead to the surrogate paradox, where a treatment appears beneficial based on the surrogate but is actually harmful with respect to the primary outcome. In this paper, we propose formal measures to assess resilience against the surrogate paradox. Our setting assumes an existing study in which the surrogate marker and primary outcome have been measured (Study A) and a new study (Study B) in which only the surrogate is measured. Rather than assuming transportability of the conditional mean functions across studies, we consider a class of functions for Study B that deviate from those in Study A. Using these, we estimate the distribution of potential treatment effects on the unmeasured primary outcome and define resilience measures including a resilience probability, resilience bound, and resilience set. Our approach complements traditional surrogate validation methods by quantifying the plausibility of the surrogate paradox under controlled deviations from what is known from Study A. We investigate the performance of our proposed measures via a simulation study and application to two distinct HIV clinical trials.

stat.ME